Perrigo gears up for cough-cold season
NEW YORK Perrigo’s latest quarterly report underscores the relatively high expectations around cough-cold-flu this year because of the novel H1N1 virus.
More importantly, Perrigo has identified a number of very-large brands that will be facing store brand competition in the coming year — MiraLax, Mucinex and Monistat-1. That’s great news for retailers. Private label offerings not only mean greater margins, but today’s economy continues to drive more consumers toward store brand trials.
For brand suppliers, private label equates to competition at the end of the day. And while that news may not be as “great,” it certainly doesn’t come as a surprise. Store brand competition, aka generic competition, is all part of an over-the-counter product lifecycle. In other words, it’s an event that can be incorporated into the bigger picture.
Typically, generic introductions against pretty-significant brand names spawn either new products under those brand names that carry a can’t-be-easily-replicated point-of-differentiation, or a whole lot of consumer messaging.
And whether it’s a new product launch or increased messaging, the end result is beneficial for both retailer and supplier — a more-aware consumer making their way to the drug store for the latest nonprescription healthcare solution.
Wild Child provides natural way to ‘Quit Nits’
LOS ANGELES Wild Child, an Australian-based natural healthcare products company showcased its Quit Nits head lice products at ECRM Health Care.
According to the company, from a survey of 1,002 parents of children ages 6 to 13, 69% of parents said it was extremely important that any lice solution they buy not contain any toxic chemicals. And 61% responded that the product should be safe for use by pregnant women. In addition, over 3-in-5 parents (64%) were bothered by the fact that many head lice treatments currently contain toxic ingredients with possible negative side effects.
Teva launches ‘Patient First’ project
WASHINGTON The world’s largest generic drug maker has started an initiative to tell stories of Americans who have difficulty paying for their prescription medications, and push for a regulatory approval pathway for biosimilars.
Teva Pharmaceuticals USA announced Thursday the “Patient First” project, part of its broader Year of Affordable Healthcare campaign.
One story is of Rob Day, who was diagnosed at age 19 with the rare blood disorder paroxysmal nocturnal hemoglobinuria, for which he must take an unspecified biotech drug that costs him $389,000 a year. Teva said a Food and Drug Administration approval pathway for biosimilars would help lower prices for drugs like the one Day takes.